Figure 1
From: Acute toxicity analysis of Disarib, an inhibitor of BCL2
Effect of oral dose of Disarib on EAC tumor progression. Swiss albino mice bearing EAC were treated with multiple doses of Disarib as follows. (a) 10 mg/kg, b.wt., 6 alternate doses. (b) 20 mg/kg b.wt., 6 alternate doses. (c) 50 mg/kg b.wt, 14 continuous doses in female mice. (d) 50 mg/kg b.wt, 14 continuous doses in male mice (ns: not significant, *p < 0.05: **p < 0.005).
